TP53 and ovarian cancer: Future studies using additional ovarian cancer cell lines with different TP53 backgrounds—such as A2780 (wild-type TP53) or OVCAR3 (mutant TP53)—will be essential to determine whether p53 signaling modulates the synergistic cytotoxic and apoptotic effects observed here.